Live
- Editorial checks in traditional press missing in social media era: Ashwini Vaishnaw
- India hopes Israel-Lebanon ceasefire deal will halt widening conflict
- Google November 2024 Core Update: Rising Volatility and SEO Concern
- Tamil Nadu Minister Predicts Udhayanidhi Stalin's Future Chief Ministerial Role
- Three Uzbek nationals arrested in Turkey for killing Israeli Rabbi
- Google hires Former Apple executive Mitul Shah as MD for its devices and services
- 'We have lost some big games against them': Van Dijk on high-stake clash vs Real Madrid
- Nushrratt Bharuccha drops sneak peek from ‘Chhorii 2’
- Army continues search for missing Meitei man, tension prevails in Imphal West
- Cars24’s net loss grows 6.4 pc to Rs 498 crore in FY24
IPO-bound Senores Pharma, Dr. Reddy's Labs launch ivermectin tablets in US
Senores Pharmaceuticals and Dr. Reddy's Laboratories, have announced the launch of ivermectin tablets USP, 3 mg. in the US market.
New Delhi: Senores Pharmaceuticals and Dr. Reddy's Laboratories, have announced the launch of ivermectin tablets USP, 3 mg. in the US market.
The tablets used to treat worm infections will be marketed by Dr. Reddy's. It is the generic version of Merck Sharp and Dohme’s Stromectol.
“We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product," said Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.
Ivermectin tablets, 3 mg brand, and generic products had US sales of approximately $20 million MAT for the twelve months ending in September 2024, according to IQVIA.
Ivermectin tablets are used to treat various parasitic infections that can affect the intestinal tract, skin, and eyes.
Senores has long-term marketing arrangements with prominent foreign and Indian pharmaceutical companies including Dr. Reddy’s Laboratories to build an extensive pipeline across diverse dosage forms and therapeutic areas.
In July, Senores filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO).
The draft red herring prospectus (DRHP) revealed that the Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 27 lakh equity shares by promoters and other selling shareholders.
The Company specialises in identifying, developing, and manufacturing a wide array of specialty, underserved, and complex pharmaceutical products, positioning itself as a preferred partner for select customers.
Utilising data analytics, research, market assessment, and experienced management; it strategically selects commercially underserved molecules and introduces them in both regulated markets mainly the US and Canada, and emerging markets across 43 countries.
